Home/Aramis Biosciences/Ken Mandell, MD, PhD

KM

Ken Mandell, MD, PhD

Chief Medical Officer

Aramis Biosciences

Therapeutic Areas

Ophthalmology Immunology

Aramis Biosciences Pipeline

Drug	Indication	Phase
A197	Dry Eye Disease	Phase 2
Preclinical Programs	Other Immuno-Inflammatory Ocular Disease	Preclinical

Leadership Team at Aramis Biosciences

David S. Tierney, MD

President and Chief Executive Officer

Chief Operating Officer

Reza Dana, MD, MPH, MSc

Scientific Co-Founder

Sunil Chauhan, DVM, PhD

Scientific Co-Founder

View full Aramis Biosciences profile